SCHEMBL17907366

SCHEMBL17907366

CCc1cc(Br)cc(C)c1NC(=O)NCCCl

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 7/20 0.42
MAPT P10636 3/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
CCR5 P51681 2/20 0.38
GAA P10253 1/20 0.38
IDH1 O75874 1/20 0.36
TSHR P16473 1/20 0.35
EPHX2 P34913 1/20 0.35
CNR1 P21554 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697640 0.77 ALDH1A1 (0.49) HPGDLMNAALDH1A1MAPTCYP1A2
SCHEMBL17907327 0.76 ALDH1A1 (0.48) LMNASMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL8415420 0.74 MAPT (0.53) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL3661793 0.71 ALDH1A1 (0.44) HPGDLMNAALDH1A1MAPTCYP2C19
SCHEMBL10603992 0.71 ALDH1A1 (0.64) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL28344029 0.69 EPHX2 (0.52) ALDH1A1MAPTEPHX2
SCHEMBL11057583 0.68 SCN5A (0.46) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL17912921 0.68 NPC1 (0.46) LMNAALDH1A1CYP1A2CYP2C19GAA
SCHEMBL18183958 0.68 ANPEP (0.43) LMNASMN1; SMN2MAPT
SCHEMBL30487417 0.68 ALDH1A1 (0.54) HPGDLMNAALDH1A1MAPTIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3042907-B1 DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) 2021-01-13 EP disclosed
US-9809604-B2 DGAT1 inhibitor and preparation method and use thereof QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) 2017-11-07 US disclosed
US-9809604-B2 DGAT1 inhibitor and preparation method and use thereof QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) 2017-11-07 US disclosed
US-20160272651-A1 DGAT1 Inhibitor and Preparation Method and Use Thereof QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) 2016-09-22 US disclosed
US-20160272651-A1 DGAT1 Inhibitor and Preparation Method and Use Thereof QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) 2016-09-22 US disclosed
EP-3042907-A1 DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF Medshine Discovery Inc. (CN) 2016-07-13 EP disclosed
EP-3042907-A1 DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF Medshine Discovery Inc. (CN) 2016-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272651-A1 DGAT1 Inhibitor and Preparation Method and Use Thereof DGAT1, DGAT2, LCAT HPGD 3613/4885LMNA 2318/4885SMN1; SMN2 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.